STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CGON Form 144: 1,000-Share Option Exercise and Proposed Sale Disclosed

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) reported a Form 144 notice indicating a proposed sale of 1,000 common shares by a person exercising stock options on 09/03/2025. The shares were acquired and paid for in cash on the same date through exercise of stock options from the issuer. The proposed sale lists Morgan Stanley Smith Barney LLC as the broker and an aggregate market value of $27,460 based on the filing. The filer also disclosed two prior 10b5-1 plan sales on 07/17/2025 totaling 2,000 shares with gross proceeds of $56,000. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small option exercise and planned sale; disclosure shows orderly disposition, not material to cap structure.

The filing documents an insider exercise of stock options and a proposed sale of 1,000 common shares through Morgan Stanley Smith Barney. Given the issuer's 76,247,581 shares outstanding and the reported aggregate market value of $27,460, the transaction is immaterial to overall capitalization. The disclosure of prior 10b5-1 sales (2,000 shares, $56,000) provides context on recent insider liquidity but does not indicate material dilution or financing activity.

TL;DR: Filing reflects routine insider compliance and use of a 10b5-1 plan; no governance red flags apparent.

The Form 144 includes the required representations and notes reliance on Rule 10b5-1 for prior sales, suggesting the seller followed established procedures for planned dispositions. There is no disclosure of undisclosed material information and no indication of accelerated or unusual insider selling that would raise immediate governance concerns based on the provided figures.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for CGON disclose?

The Form 144 discloses a proposed sale of 1,000 common shares acquired by exercise of stock options on 09/03/2025, with Morgan Stanley Smith Barney as broker and an aggregate market value of $27,460.

When were the shares acquired and how were they paid for?

The 1,000 shares were acquired on 09/03/2025 by exercise of stock options and paid for in cash on the same date.

Did the filer report any sales in the past three months?

Yes. The filing discloses 10b5-1 sales on 07/17/2025 of 2,000 shares with gross proceeds of $56,000.

Who is the broker handling the proposed sale?

The named broker is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

How many shares are outstanding for CGON according to the filing?

The filing reports 76,247,581 shares outstanding.
CG Oncology, Inc.

NASDAQ:CGON

CGON Rankings

CGON Latest News

CGON Latest SEC Filings

CGON Stock Data

3.44B
73.31M
1.17%
112.6%
13.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE